Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Clinical Immuno-Oncology
- 1st Edition - March 5, 2023
- Author: John E. Niederhuber
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 7 7 6 3 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 6 2 3 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 7 7 6 4 - 0
Offering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteOffering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and molecular mechanisms involved in cancer initiation and progression. The text reviews the development of tumor specific antigens and the challenges of developing cancer immunotherapies. Every effort is made to relate the fundamental aspects of host immunity to the efficacy of current immunotherapies and how they work in conjunction with the immune system to combat cancer. This foundational resource explains the basics of cancer immunotherapy, discusses best practices, and provides recommendations from experienced clinicians in the field. Dr. John E. Niederhuber and a team of expert contributing authors provide clinically focused information essential for integrating these new therapies into practice—making this an ideal resource for fellows, practitioners, and other cancer team members in medical oncology, radiation oncology, cancer surgery, immunology, and cancer research.
-
Offers balanced and synthesized content on clinical science, clinical and translational research, and evidence-based practice for cutting-edge immunotherapies.
-
Discusses clinical applications of immunotherapies in common types of cancer including melanoma, breast cancer, pancreatic cancer, colon and rectum cancer, prostate cancer, leukemias, and hematologic malignancies.
-
Includes dedicated chapters on immune responses, innate immunity, active immunization against cancer, and cell-based therapies by leading experts.
-
Covers key topics such as cancer immunotherapy in the presence of COVID-19, immunotherapeutics, new findings concerning the role of the microbiome in immunotherapy, advances in engineered cell-based therapies, and active immunization against cancer.
-
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.
Medical oncologists, radiation oncologists, oncology surgeons, immunologists – practicing and fellows
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Acknowledgments
- Dedication
- List of Illustrations
- List of Tables
- 1. Development and structure of the lymphoid system
- Introduction
- Overview of the lymphatic system
- Embryonic development of the lymphatic system
- Heterogeneity of lymphatic endothelial cells and organ-specific lymphatic vessels
- Lymph node microscopic structure and function
- The lymphatic system and cancer
- Conclusions
- Key references
- References
- 2. The chemistry, structure, and function of immunoglobulins
- The structure of immunoglobulins
- Antibody isotypes
- The genetic basis of immunoglobulin diversity
- Glycosylation of Ig heavy chains
- Antibody-dependent cellular cytotoxicity
- Therapeutic monoclonal antibodies
- Key references
- References
- 3. The role of the complement system in cancer etiology and management
- Introduction
- Complement activation pathways
- Complement effector molecules
- Complement therapeutics
- Complement response to cancer
- Complement dependent cytotoxicity and cancer
- Complement regulatory proteins and cancer
- Complement activation in the tumor microenvironment enhances tumor growth
- The role of complement activation in cancer progression
- Potential application of anticomplement cancer therapies (C3aR/C5aR/IL-10 pathway)
- Conclusions
- Key references
- References
- 4. Cancer and the science of innate immunity
- Introduction
- The cellular components of the innate immune response
- Innate immune networks in the promotion of tumor growth, immune suppression, and metastasis
- Innate immune sensing during cancer progression
- Cancer therapies targeting innate immunity
- Key references
- References
- 5. Tumor antigenicity and cancer as non-self
- Introduction
- Identification of human tumor antigens
- What the future holds—integrating immune response and network biology
- Key references
- References
- 6. Tumor immune surveillance
- The concept of immune surveillance in cancer
- Mouse models stimulate resurgence of cancer immunosurveillance
- Current experimental evidence supporting tumor immune surveillance
- Immune editing in cancer
- Tumor-associated antigens
- Antigen-specific immune surveillance of oncogene-induced premalignant senescent cells
- Microbiome and microbial proteins
- Cancer in the immunocompromised host
- Key references
- References
- 7. The essential elements of adaptive immunity and their relevance to cancer immunology
- Introduction
- Recognition of tumor antigens: Specificity engendered by the T-cell and B-cell receptors
- Antigen receptor signaling
- Costimulation
- Metabolic adaptations used by lymphocytes
- Tumor antigen presentation: Dendritic cells
- Integrating innate and adaptive immunity to cancer
- T-cell subsets in cancer immunity
- Helper CD4+ T cells
- Biologic variables in adaptive immunity
- Key references
- References
- 8. Cancer—avoiding immune detection
- Introduction
- The presence of tumor immune suppression
- Downregulation of or actual loss of MHC class I and II expression
- Immune checkpoints and checkpoint ligands
- Antigen loss variants—loss of mRNA translation
- The development of actual tumor cell tolerance
- Tumor cell–derived immune suppression
- The tumor microenvironment, inflammation, and immune escape
- Dendritic cells and inflammation
- Myeloid-derived tumor suppressor cells
- CD4+ T cells and tregs in cancer inflammation
- Cancer-associated fibroblasts
- Tumor-associated macrophages
- Nonclassic HLA molecules—HLA-G
- Some concluding thoughts
- Key references
- References
- 9. Vaccines and active immunization against cancer
- Introduction
- Cancer vaccines
- Antigen choice
- Cancer vs pathogen vaccines
- Antigen delivery systems
- Key references
- References
- 10. The major clinical components of cancer immunotherapy (modulating cell-mediated immune mechanisms)
- The role and application of checkpoint blockade
- The role and application of cell-based therapies
- The role and application of antibody-based therapies
- The role and application of cancer vaccines
- Combination immunotherapies in practice and clinical research trials
- Acknowledgment
- Disclosure
- Key references
- References
- 11. The microbiome and cancer immunotherapy
- Introduction
- The microbiome and immune system development
- The microbiome and cancer initiation and progression
- The microbiome and cancer immunotherapy
- The intestinal microbiome and ICI immunotherapy
- The intestinal microbiome and cell-based immunotherapy
- Pharmacomicrobiomics
- Some thoughts in conclusion
- Key references
- References
- 12. The clinical application of immuno-therapeutics
- Introduction
- Historical background
- General classes of cancer immunotherapy agents
- Skin cancer
- Lung cancer
- Triple-negative breast cancer
- Gastrointestinal malignancies
- Gynecologic malignancies
- Genitourinary malignancies
- Prostate cancer
- Head and neck squamous cell carcinoma
- Tissue/site-agnostic malignant solid tumors
- Hematologic malignancies
- Immune-related toxicities associated with checkpoint blockade
- Toxicities associated with CAR T-cell therapy
- Prospective directions
- Key references
- References
- 13. The effect of COVID-19 on cancer immunotherapy and cancer care
- Introduction
- The emergence and global effect of SARS-CoV-2
- SARS-CoV-2 structure and biology
- The angiotensin-converting enzyme 2, SARS-CoV-2 infection, and cancer
- SARS-CoV-2 viral infection and innate immunity
- The adaptive immune response to SARS-CoV-2 infection
- COVID-19 infection in patients with cancer
- COVID-19 vaccination and the patient with cancer
- COVID-19 and cancer therapy
- Effect of COVID-19 pandemic on clinical cancer care and cancer clinical trials research
- Post-acute SARS-CoV-2 syndrome and its effect on the patient with cancer
- Some concluding thoughts
- Key references
- References
- Index
- No. of pages: 336
- Language: English
- Edition: 1
- Published: March 5, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780323877633
- eBook ISBN: 9780443286230
- eBook ISBN: 9780323877640
JN
John E. Niederhuber
Dr John Niederhuber is formerly Executive Vice President of the Inova Health System; President and CEO of the Genomics and Bioinformatics Research Institute in Fairfax, Virginia; Professor in the Department of Public Health Sciences at the University of Virginia School of Medicine in Charlottesville, Virginia; and Deputy Director of The Johns Hopkins Clinical Research Network in Baltimore, Maryland. He recently retired from these positions and remains Adjunct Professor of Oncology and Surgery at Johns Hopkins University and is also currently the lead editor of Abeloff’s Clinical Oncology, 6th edition (2019). Dr Niederhuber is highly well connected and respected in the medical oncology and surgical oncology fields.
Affiliations and expertise
Adjunct Professor, Departments of Surgery and Oncology; Deputy Director, The Johns Hopkins Clinical Research Network, Johns Hopkins University School of Medicine, Baltimore, Maryland